Joseph Tucker
On April 24, 2026, the Board of Directors (the “Board”) of Lakewood-Amedex Biotherapeutics Inc. (the “Company”) appointed Dr. Joseph Tucker to fill a vacancy and serve as a member of the Board, effective April 24, 2026.
Highest-materiality recent filing
Investor deck highlights Bisphosphocin® compounds, a novel class of fast-acting, broad-spectrum antimicrobials.
Lakewood-Amedex announces 1-for-10 reverse stock split effective June 19, 2026
Reverse split ratio: 1-for-10; effective at 4:01 p.m. ET on June 19, 2026; trading starts split-adjusted on Nasdaq June 22.
Appoints Joseph Tucker to board; $6,000/quarter stock + 33,784 warrants at $10
Dr. Joseph Tucker appointed to Board, effective April 24, 2026, until 2027 annual meeting.
On April 24, 2026, the Board of Directors (the “Board”) of Lakewood-Amedex Biotherapeutics Inc. (the “Company”) appointed Dr. Joseph Tucker to fill a vacancy and serve as a member of the Board, effective April 24, 2026.
Max materiality 0.65 · Median 0.50 · Most common event other_material